Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Readers on

mendeley: 40 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 11,424 followers.

RT @OncoGir: 🧬 Publicats els resultats d'aquest estudi fase I internacional amb Enadenotucirev, un vector adenoviral quimèric, per càncer d…

🧬 Publicats els resultats d'aquest estudi fase I internacional amb Enadenotucirev, un vector adenoviral quimèric, per càncer d'ovari platí-resistent, en el que ha participat la Dra. Barretina, referent de tumors ginecològics del nostre servei. https://t.…

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial https://t.co/JkqjHmnBBP

肿瘤选择性腺病毒 enadenotucirev 联合或不联合紫杉醇在铂类耐药卵巢癌中的安全性和有效性：1 期临床试验 https://t.co/kbBVpMLnhW

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.